Endo-cannabinoids are the substances our bodies naturally make to stimulate our endocannabinoid receptors. The two of these molecules that are understood the most, are called anandamide and 2-arachidonoylglycerol. They are synthesized as required from inside the cell membrane arachidonic acid, they have a local effect on the body and short half-life then they are degraded rapidly by the enzymes, amide hydrolase and monoacylglycerol lipase.


Anandamide is produced in the brain, which binds to the endocannabinoid receptors. A substance produced within our bodies it is considered that endocannabinoids are known to bind our endocannabinoid receptor system.

This neurotransmitter was found to do much more then achieve a state of motivation, heightened happiness, the thought process, memory and movement control. Anandamide, comparing to other neurotransmitters, is fragile and breaks down rapidly within the human body which is why this doesn’t produce a perpetual state of bliss.The other main endocannabinoid, the 2-Arachidonoylglycerol (2-AG) along with anandamide has an effect on our bodies Cannabinoid receptors. 2-AG is the primary binding molecule for the CB2 receptor, 2-AG is the most infinite endocannabinoid discovered in the body. Similar to anandamide is thought to be an important role incorporating with a healthy lifestyle.

2AG (2-Arachidonyl glycerol)

2-Arachidonoylglycerol (2-AG) is the main endocannabinoid, found in our bodies.that work in conjunction with anandamide and has an effect, when binding to the CB receptors within our bodies. Specifically, 2-AG could be a full agonist of each CB receptor, and is the primary matter (binding molecule) for the CB2 receptor.

2-AG is the most abundant endocannabinoid found within the body, and like anandamide, is believed to play a vital role within the regulation of general health sustaining a healthy endocannabinoid system.


2-Arachidonyl glyceryl ether (noladin ether)

In 2001, a third, ether-type endocannabinoid, 2-arachidonyl group ether (noladin ether), was isolated from porcine brain.

Prior to this discovery, it had been synthesized as a stable analog of 2-AG; so, some contention remains over its classification as Associate in Nursing endocannabinoid, as another cluster did not
detect the substance at "any considerable amount" within the brains of many completely different classspecies.
It binds primarily to the CB1 receptor, and solely weak to the CB2 receptor.

N-Arachidonoyl dopamine (NADA)

Discovered in 2000, N-Arachidonoyl dopamine (NADA) preferentially binds to the CB1 receptor.
Like anandamide, NADA is also an agonist for the vanilloid receptor sub type 1 (TRPV1), a member of the vanilloid receptor family.Virodhamine (OAE)

A fifth endocannabinoid, virodhamine, or O-arachidonoyl-ethanolamine (OAE), was discovered in June 2002.
Although it's a full agonist at CB2 and a partial agonist at CB1, it behaves as a CB1 antagonist in.
In rats, virodhamine was found to be gift at comparable or slightly lower concentrations than anandamide within the brain, however 2- to 9-fold higher concentrations peripherally

Lysophosphatidylinositol (LPI)

Recent proof has highlighted lysophosphatidylinositol because the endogenous substance to novel endocannabinoid receptor GPR55, creating it a powerful rival because the sixth endocannabinoid.